BrainScope TBI

The BrainScope TBI (Ahead 500) is a neurodiagnostic device intended to aid in the multi-modal assessment of closed head injuries at the point-of-care, utilizing electroencephalography (EEG) and computerized cognitive tests. Its science relies on proprietary algorithms to generate indices like the Concussion Index (CI), Structural Injury Classification (SIC), and Brain Function Index (BFI), which have been clinically validated for specific age groups to evaluate for the presence and severity of brain injury and dysfunction.

The BrainScope TBI, particularly the Ahead 500 model, is a portable, non-invasive, point-of-care neurodiagnostic device designed to assist healthcare professionals in evaluating patients with closed head injuries, including concussions and mild traumatic brain injuries (mTBI). It employs a multi-modal assessment strategy, integrating electroencephalogram (EEG) analysis collected via a frontal Electrode Headset with computerized cognitive performance tests and digitized standard clinical assessment tools. The device features a handheld unit with a touchscreen interface and wireless capabilities for data management. Key outputs include the Structural Injury Classification (SIC) for assessing the likelihood of CT-detectable brain injury in adults (18-85 years, GCS 13-15), and the Brain Function Index (BFI) for the same age group, both EEG-based and retained from the predecessor Ahead 400 model. A primary enhancement in the Ahead 500 is the Concussion Index (CI), a multi-parameter algorithm combining EEG data, neurocognitive measures, and clinical symptoms, indicated for evaluating concussion in individuals aged 13-25 (GCS 15) within 72 hours of injury. Clinical validation for the CI in a study of 580 subjects demonstrated a sensitivity of 85.99% and specificity of 70.78%. The SIC was validated in the B-AHEAD III study (720 subjects, 18-85 years, GCS 12-15), showing 92.31% sensitivity and 51.60% specificity compared to CT scans, while the BFI showed utility in assessing functional impairment. The system also provides quantitative cognitive performance tests for ages 13-85 and is supported by research into EEG biomarkers and machine learning for symptom prediction.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the Concussion Index (CI) algorithm specifically weigh EEG data versus neurocognitive measures and clinical symptoms, and can this weighting be adjusted for different patient presentations?; What are the specific neurocognitive tests included, and how do their individual performances correlate with the overall CI, SIC, and BFI scores beyond the combined index?; Given the reported specificity of 51.60% for the Structural Injury Classification (SIC), what is the anticipated impact on downstream resource utilization, such as unnecessary CT scans or specialist referrals, in real-world clinical settings?; The B-AHEAD III study reported one device-related burning sensation; what specific design modifications or user training protocols have been implemented in the Ahead 500 to mitigate this risk?; How does the device's Brain Function Index (BFI) differentiate between acute injury effects and pre-existing neurological conditions or baseline cognitive variations in the diverse 18-85 age group?